As molecular testing becomes increasingly integrated into routine oncology care, the accurate interpretation and clear reporting of genomic variants are essential for guiding clinical decision-making. This workshop will explore best practices and current challenges in variant interpretation, with a focus on solid tumors.

Participants will gain practical insights into leveraging databases, classification frameworks, and evolving evidence to ensure clinically meaningful reports

Speaker; Philip Jermann, Director Medical Affairs professional, EMEA, Thermo Fisher Scientific, Clinical Sequencing Division